Related Experiment Video
Updated: Apr 5, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer
Jan J Melenhorst1, Simon F Lacey, Felipe Bedoya
1University of Pennsylvania, Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapies, Product Development & Correlative Sciences laboratory, 3400 Civic Center Boulevard, Philadelphia, PA 19104-5156, United States.
Abstract:
The chimeric antigen receptor (CAR) technology started out as a tool to understand lymphocyte biology but rapidly developed into a T cell therapeutic agent for the treatment of cancers. Here, we describe the technological advances in the field of CARs and highlight critical components of its success. Additionally, we describe how various laboratories have worked toward developing new, safer, and more potent CARs for cancer.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...

